Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pluristem Advances Second Cell Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pluristem Advances Second Cell Therapy

Will begin large-scale manufacturing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pluristem Therapeutics, Inc. has completed development of its second major cell product line and can now begin large-scale manufacturing for anticipated studies in a range of hematologic conditions. The cell product candidate, PLX-RAD, was created using Pluristem’s three dimensional cell expansion technology platform. The company’s first product, PLX-PAD, is currently in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension.
 
“We’ve just completed a two-year development cycle for our PLX-RAD cells, and have also developed new manufacturing equipment, methods and know-how. We believe that our state-of-the-art technology platform can be used to create additional cell products from the placenta, tailored to potentially deliver targeted treatments for a variety of new indications,” stated Zami Aberman, chairman and chief executive officer of Pluristem.  
 
“Our technology platform, robust manufacturing capabilities and broad IP portfolio open the door for potential institutional and commercial partners, and we’re pleased with the level of interest we have received in our technology platform. Pluristem is in a unique position to be a leader in the cell therapy industry,” Mr. Aberman concluded.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics